In the GSE4412-GPL97 database (n = 74) containing 67% malignant grade IV GBM and 32.4% astrocytomas or other glioma patients, those with low Znf179 expression levels (n = 31) were significantly associated with a poor prognosis and survival rates (p = 0.013) (Fig. 5A). This evidence concerns the gene RNF112 and astrocytoma (excluding glioblastoma).